Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial-Reference-Cited by-同舟云学术

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

Published:2019-03 Issue:3 Volume:19 Page:253-264
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Aboud Michael,Kaplan Richard,Lombaard Johannes,Zhang Fujie,Hidalgo José A,Mamedova Elmira,Losso Marcelo H,Chetchotisakd Ploenchan,Brites Carlos,Sievers Jörg,Brown Dannae,Hopking Judy,Underwood Mark,Nascimento Maria Claudia,Punekar Yogesh,Gartland Martin,Smith Kimberly

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference25 articles.

1. The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study;Estill;Lancet HIV,2016

2. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach,2016

3. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance,2018

4. Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis;Kanters;Lancet HIV,2017

5. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review;Brown;AIDS,2006

Cited by 138 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of Viral Suppression in Paediatric Populations: Implications for the Transition to Dolutegravir-Based Regimens in Cameroon: The CIPHER-ADOLA Study;Biomedicines;2024-09-12

2. Switching Human Immunodeficiency Virus Therapy;Infectious Disease Clinics of North America;2024-09

3. Treatment Management Challenges in Naïve and Experienced HIV-1-Infected Individuals Carrying the M184V Mutation;Viruses;2024-08-30

4. Acquired Human Immunodeficiency Virus Type 1 Drug Resistance in Rhode Island, USA, 2004–2021;The Journal of Infectious Diseases;2024-07-23

5. Development and Optimization of Oligonucleotide Ligation Assay (OLA) Probes for Detection of HIV-1 Resistance to Dolutegravir;Viruses;2024-07-19